Atea Pharmaceuticals Inc (AVIR)

11:31 AM

Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace

11:31 AM

Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com

Apr 01, 2025

Mar 31, 2025

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times

Mar 31, 2025

Mar 29, 2025

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 29, 2025

Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com

Mar 26, 2025

Mar 26, 2025

Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch

Mar 26, 2025

Mar 26, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan

Mar 26, 2025

Mar 26, 2025

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com

Mar 26, 2025

Mar 26, 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener

Mar 26, 2025

Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 24, 2025

Mar 22, 2025

Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire

Mar 22, 2025

Mar 21, 2025

Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener

Mar 21, 2025

Mar 21, 2025

Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control - StockTitan

Mar 21, 2025

Mar 21, 2025

Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Insider Monkey

Mar 21, 2025

Mar 19, 2025

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time - StockTitan

Mar 19, 2025

Mar 10, 2025

Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com Australia

Mar 10, 2025

Mar 10, 2025

What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World

Mar 10, 2025

Mar 09, 2025

William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World

Mar 09, 2025

Mar 09, 2025

Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN

Mar 09, 2025

Mar 08, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025

Mar 08, 2025

BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat

Mar 08, 2025

Mar 07, 2025

Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks

Mar 07, 2025

Mar 07, 2025

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga

Mar 07, 2025

Mar 06, 2025

Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 06, 2025

Mar 06, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian

Mar 06, 2025

Mar 06, 2025

Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan

Mar 06, 2025

Mar 01, 2025

Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 01, 2025

Feb 27, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals to Host Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq

Feb 27, 2025

Feb 27, 2025

When Will Atea Pharmaceuticals Reveal Its Antiviral Pipeline Progress? Key Date for Biotech Investors - StockTitan

Feb 27, 2025

Feb 27, 2025

Atea Pharmaceuticals Appoints Arthur Kirsch as Class I Director Amid Voting Agreement Disclosure - Defense World

Feb 27, 2025

Feb 25, 2025

Atea Pharmaceuticals appoints Arthur Kirsch to Board By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 24, 2025

Atea Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals Appoints Arthur Kirsch as Director - TipRanks

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada

Feb 24, 2025

Feb 24, 2025

Atea Pharmaceuticals appoints new board member - Investing.com India

Feb 24, 2025